ChB MD - Propanc Biopharma CTO Officer
| PPCB Stock | USD 0.0003 0.00 0.00% |
Insider
ChB MD is CTO Officer of Propanc Biopharma
| Age | 74 |
| Phone | 61 3 9882 0780 |
| Web | https://www.propanc.com |
Propanc Biopharma Management Efficiency
The company has return on total asset (ROA) of (13.0742) % which means that it has lost $13.0742 on every $100 spent on assets. This is way below average. Propanc Biopharma's management efficiency ratios could be used to measure how well Propanc Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| MD MBA | Rezolute | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Brian MD | Rezolute | 49 | |
| Joseph Hazelton | Dyadic International | 48 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| LLM JD | Rezolute | 63 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Antony CPA | Forte Biosciences | 57 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
Management Performance
| Return On Asset | -13.07 |
Propanc Biopharma Management Team
Elected by the shareholders, the Propanc Biopharma's board of directors comprises two types of representatives: Propanc Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Propanc. The board's role is to monitor Propanc Biopharma's management team and ensure that shareholders' interests are well served. Propanc Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Propanc Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Nathanielsz, CEO, Treasurer, Secretary, Director | ||
| ChB MD, CTO Officer | ||
| Pr Kutz, Chief Board |
Propanc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Propanc Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Shares Owned By Insiders | 1.60 % | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Net Income | (2.66 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.